Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2328)
  2. Meeting Abstract (1851)
  3. Review (147)
  4. Book Section (127)
  5. Editorial (98)
  6. Guidelines (37)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (22)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4697)
  2. Department of Medicine (4695)
  3. Center for Pancreatic Cancer Research (2291)
  4. Surgery (1052)
  5. Survivorship Research (1002)
  6. Epidemiology and Biostatistics (836)

More Groups

People
  1. Leonard Saltz (792)
  2. Eileen O'Reilly (790)
  3. Ghassan Abou-Alfa (575)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (436)

More People

Years
  1. 2025 (173)
  2. 2024 (308)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1287)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (142)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1373)
  2. Oxford University Press (448)
  3. Elsevier Inc. (410)
  4. Springer (314)
  5. American Association for Cancer Research (280)
  6. Wiley Blackwell (240)

More Publishers

Results (4697)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors
    Meeting Abstract

    Love, N.; Bylund, C.; Meropol, N. J.; Marshall, J. L.; Curley, S. A.; Ellis, L. M.; Grothey, A.; Lenz, H. J.; Saltz, L. B.; Elder, M. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Is neoadjuvant (neoadj) treatment necessary prior to liver resection in patients with resectable liver metastases (mets) from colorectal carcinoma (CRC) treated with post-resection hepatic arterial infusion (HAI) plus systemic (SYS) chemotherapy
    Meeting Abstract

    Kemeny, N. E.; Capanu, M.; Huitzil-Melendez, F.; Haviland, D.; Fong, Y.; Jarnagin, W.; Blumgart, L.; DeMatteo, R.; D'Angelica, M.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Small cell carcinoma of the esophagus: Review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Ku, G. Y.; Kelsen, D.; Minsky, B.; Rusch, V.; Bains, M.; Ilson, D. H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Evaluation of the feasibility of expression microarray analysis in endoscopically obtained biopsies of gastric carcinoma and their clinical applicability
    Meeting Abstract

    Jhawer, M. P.; Qin, L.; Gerdes, H.; Klimstra, D.; Schattner, M.; Viale, A.; Gonen, M.; Schwartz, G.; Kelsen, D.; Shah, M.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Initial findings from the Memorial Sloan-Kettering Early Onset and Familial Gastric Cancer Registry (EOFGCR)
    Meeting Abstract

    Harlan, M.; Sheehy, E.; Randazzo, J.; Schrag, D.; Kemeny, M. M.; Kelsen, D. P.; Shah, M. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Prognostic factors (PF) in advanced hepatocellular carcinoma (AHCC): Multivariate analysis and comparison between staging systems (SS) in patients (pts) treated at Memorial Sloan-Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Huitzil, F. D.; Capanu, M.; Jacobs, G.; Smith, W.; O'Reilly, E.; Shah, M.; Schwartz, G. K.; Saltz, L. B.; Kelsen, D. P.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer
    Meeting Abstract

    Garrison, L.; Cassidy, J.; Saleh, M.; Lee, F.; Mena, R.; Fuloria, J.; Chang, V.; Ervin, T.; Stella, P.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bevacizumab (BV) in combination with oxaliplatin-containing regimens: An analysis of two phase III studies
    Meeting Abstract

    Giantonio, B. J.; Meropol, N. J.; Catalano, P. J.; Ng, V.; Oliver, R.; Sirzen, F.; Leonard, S.; Cassidy, J.; Benson, A. B.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC)
    Meeting Abstract

    Goldberg, R. M.; Köhne, C. H.; Seymour, M. T.; de Gramont, A.; Porschen, R.; Saltz, L.; Rougier, P.; Tournigand, C.; Grothey, A.; Sargent, D. J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials
    Meeting Abstract

    Folprecht, G.; Seymour, M. T.; Saltz, L.; Douillard, J. Y.; Stephens, R. J.; Van Cutsem, E.; Rougier, P.; Maughan, T. S.; Köhne, C. H.; Ironotecan Meta-analysis Group
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save